系统综述与荟萃分析:对乙酰氨基酚与非甾体抗炎药(NSAIDs)使用与克罗恩病及溃疡性结肠炎病情加重的关联
该系统综述与荟萃分析检索截至2017年3月1日的文献,纳入1983至2016年间18篇出版物,评估对乙酰氨基酚与NSAIDs(含COX-2抑制剂)使用与克罗恩病(CD)及溃疡性结肠炎(UC)病情加重的关联。合并分析显示NSAIDs与CD加重(RR 1.42,95%CI 0.65-3.09)及UC加重(RR 1.52,95%CI 0.87-2.63)均无统计学显著关联;对乙酰氨基酚与UC加重(RR 1.40,95%CI 0.96-2.04)无显著关联,与IBD加重(RR 1.56,95%CI 1.22-1.99)的关联有统计学意义。低偏倚风险研究的敏感性分析显示NSAIDs与CD加重风险显著增加(RR 1.53,95%CI 1.08-2.16),与UC加重无显著关联(RR 0.94,95%CI 0.36-2.42)。
要点
- NSAIDs与CD加重合并RR 1.42(95%CI 0.65-3.09),与UC加重合并RR 1.52(95%CI 0.87-2.63),均无统计学显著关联。
- 对乙酰氨基酚与UC加重RR 1.40(95%CI 0.96-2.04)无显著关联;与IBD加重RR 1.56(95%CI 1.22-1.99)有统计学意义。
- 低偏倚风险研究敏感性分析:NSAIDs与CD加重RR 1.53(95%CI 1.08-2.16)显著,与UC加重RR 0.94(95%CI 0.36-2.42)不显著。
核心结论
- 与普遍接受的观点相反,未发现NSAIDs使用与CD及UC病情加重风险之间存在一致性关联。
- 对乙酰氨基酚与病情加重关联的证据也不一致,原文指出需进一步研究。
研究设计与样本
- 系统综述与荟萃分析,检索Medline、Embase、Cochrane及其他试验注册库至2017年3月1日。
- 纳入1983年至2016年间18篇出版物,采用Newcastle-Ottawa量表进行质量评价,使用随机效应模型计算合并相对风险(RR)及95%CI。
主要发现
- NSAIDs使用与CD加重的合并RR为1.42(95%CI 0.65-3.09),异质性I²=60.3%;与UC加重的合并RR为1.52(95%CI 0.87-2.63),异质性I²=56.1%。
- 对乙酰氨基酚使用与UC加重的合并RR为1.40(95%CI 0.96-2.04),异质性I²=45.6%;与IBD加重的合并RR为1.56(95%CI 1.22-1.99),异质性I²=0.0%。
- 限于低偏倚风险研究的敏感性分析显示NSAIDs与CD加重风险显著增加(RR 1.53,95%CI 1.08-2.16),与UC加重无显著关联(RR 0.94,95%CI 0.36-2.42)。
局限性
- 原文指出需进一步研究以明确对乙酰氨基酚与病情加重之间的关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Unlike acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs) have generally been thought to be associated with increased risk of IBD exacerbation. AIM: To carry out a systematic review and meta-analysis of previous studies examining the association between acetaminophen and NSAIDs including cyclooxygenase (COX-2) inhibitors use, and risk of Crohn's disease (CD) and ulcerative colitis (UC) exacerbation. METHODS: We identified published manuscripts and abstracts through 1 March 2017 by systematic search of Medline, Embase, Cochrane and other trial registries. Quality assessment was done using Newcastle-Ottawa scale and random-effect meta-analysis using pooled relative risks (RRs) and 95% CIs were calculated. RESULTS: Eighteen publications between years 1983 and 2016 were identified. For the meta-analysis, pooled RRs of disease exacerbation with NSAIDs use were (1.42, 95% CI, 0.65-3.09), I2 = 60.3% for CD, and (1.52, 95% CI, 0.87-2.63), I2 = 56.1% for UC. The corresponding values for acetaminophen use were (1.40, 95% CI, 0.96-2.04), I2 = 45.6% for UC, and (1.56, 95% CI, 1.22-1.99), I2 = 0.0% for IBD. Sensitivity analyses limited to studies with low risk of bias showed a significantly increased risk of CD exacerbation (1.53, 95% CI, 1.08-2.16) but not UC (0.94, 95% CI, 0.36-2.42) with NSAIDs use. CONCLUSIONS: Contrary to generally accepted belief, we did not find a consistent association between NSAIDs use and risk of CD and UC exacerbation. There was also no consistent evidence for association with acetaminophen although further studies are needed.
引用
- Moninuola OO, Milligan W, Lochhead P, et al. Systematic review with meta-analysis: association between acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) and risk of Crohn's disease and ulcerative colitis exacerbation. Aliment Pharmacol Ther. 2018. PMID: 29620794. doi:10.1111/apt.14606
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。